European Journal of Cancer
Volume 46, Issue 5 , Pages 901-911, March 2010

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

  • Hester van Cruijsen

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Emile E. Voest

      Affiliations

    • Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Cornelis J.A. Punt

      Affiliations

    • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
    • ,
  • Klaas Hoekman

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Petronella O. Witteveen

      Affiliations

    • Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Martijn R. Meijerink

      Affiliations

    • Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Thomas A. Puchalski

      Affiliations

    • AstraZeneca, Wilmington, DE, USA
    • Present address: Centocor, Chesterbrook, PA, USA.
    • ,
  • Jane Robertson

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Owain Saunders

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Juliane M. Jürgensmeier

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Carla M.L. van Herpen

      Affiliations

    • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
    • ,
  • Giuseppe Giaccone

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 12N226, 10 Center Drive, Bethesda, MD 20892-190, USA. Tel.: +1 301 496 4916; fax: +1 301 402 0172.

Received 23 September 2009; received in revised form 7 December 2009; accepted 14 December 2009. published online 11 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(09)00935-6

doi:10.1016/j.ejca.2009.12.023

European Journal of Cancer
Volume 46, Issue 5 , Pages 901-911, March 2010

Article Tools

* Image Usage & Resolution